A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
Condition:   Heart Failure With Preserved Ejection Fraction Interventions:   Drug: sacubitril/valsartan;   Drug: Enalapril;   Drug: Valsartan;   Drug: Placebo to match sacubitril/valsartan;   Drug: Placebo to match enalapril;   Drug: Placebo to match valsartan Sponsor:   Novartis Pharmaceuticals Not yet recruiting - verified February 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 23, 2017 Category: Research Source Type: clinical trials